Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate  by Poortmans, Philip
Comment
2104 www.thelancet.com   Vol 383   June 21, 2014
Postmastectomy radiation in breast cancer with one to three 
involved lymph nodes: ending the debate
Many trials in breast cancer have investigated various 
aspects of locoregional and systemic treatments. 
Combination of the results of these trials in a meticulous 
meta-analysis, as has been done several times by 
the Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG), ﬁ lls the gaps in evidence and knowledge by 
conclusively showing signiﬁ cant trends and diﬀ erences.
Following publication of the eﬀ ect of radiotherapy 
after breast-conserving therapy,1 the EBCTCG now 
presents results for postmastectomy radiotherapy 
in The Lancet.2 The central issue is the role of 
postmastectomy radiotherapy in patients with one to 
three involved axillary lymph nodes, which is currently a 
matter of debate in many countries.3 Whereas the earlier 
results were essentially conﬁ rmed in this report,1,4 we get 
more insight into the eﬀ ect of the extent of lymph-node 
involvement, the number of examined axillary lymph 
nodes, and the use of adjuvant systemic therapy. Overall, 
postmastectomy radiotherapy improves locoregional 
disease-free survival, overall disease-free survival, and 
breast-cancer-speciﬁ c survival for all patients with 
involvement of axillary lymph nodes, irrespective of the 
number of involved lymph nodes and of administration 
of adjuvant systemic therapy. This improvement is not 
only statistically signiﬁ cant, but also clinically relevant.
The proportional reductions in rates of recurrence 
and mortality were independent of the administration 
of systemic therapy. Whether this ﬁ nding also applies 
to patients treated with more contemporary regimens 
remains to be seen. We need to continue evaluating 
results of the contemporary multidisciplinary approach 
in breast cancer to better understand the complex 
interaction between respective contributions of 
systemic and locoregional treatments to the ﬁ nal 
outcome, including survival and toxic eﬀ ects. As 
Punglia and colleagues5 pointed out, the contribution 
of improved locoregional control to survival depends 
on the eﬀ ectiveness of systemic treatment. Punglia 
and colleagues’ bell-shaped curve,5 however, misses 
the component of metastatic risk of the primary 
tumour. Combining both, the inﬂ uence of both the 
eﬀ ectiveness of systemic therapy and metastatic risk 
of the primary tumour can be used to estimate the 
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Figure: Combined hypothetical beneﬁ t of local tumour control on survival with increasing eﬀ ectiveness of 
systemic therapy (ST) and decreasing risk of distant metastases of the primary tumour
Patients in the left part of the slope have high-risk disease without eﬀ ective systemic therapy and are not expected 
to beneﬁ t from improving locoregional treatments. For patients in the right part of the slope, treatment 
deintensiﬁ cation (surgery, radiation, or systemic therapy) might be appropriate. The middle group will represent 
most past and current patients with breast cancer, for whom an optimum multidisciplinary approach results in the 
greatest beneﬁ t. 
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contribution of improved locoregional treatment 
to the ﬁ nal outcome (ﬁ gure). For many patients, 
improvement of systemic therapy will decrease the 
risk of death due to distant metastasis, after which the 
importance of optimised locoregional control—which 
will already be better after systemic treatment—will, 
relatively, contribute more to survival.
As the EBCTCG outlines,2 interpretation of the ﬁ ndings 
should take into account the decreased locoregional 
recurrence rates during recent decades owing to 
improvements in diagnostic and therapeutic procedures. 
However, the complex interaction between locoregional 
and distant recurrences as a ﬁ rst event (illustrated in 
the appendix of the Article) clearly shows that the two 
types of event should not be considered individually 
as separate events but taken together. Improvements 
in locoregional treatments will only directly aﬀ ect 
the development and further spread of subclinical 
locoregional tumour deposits. Moreover, we should 
realise that the incidence of locoregional recurrences 
at diagnosis of distant metastasis is underestimated 
because of a lack of relevance of its detection and no 
routine accurate diagnosis, especially for regional 
recurrences, making the latter a poor endpoint for trials 
evaluating locoregional treatments.6 Also of note in this 
respect is the ﬁ nding that the one in four rule from earlier 
EBCTCG meta-analyses (ie, for every four recurrences 
avoided about one life was saved) cannot be generalised 
to all patient groups; in the present analysis, about one 
breast cancer death at 20 years was avoided for every 
1·5 recurrences avoided at 10 years.1,2,4
This meta-analysis also shows the importance of 
the extent of axillary surgery, with a greater beneﬁ t of 
postmastectomy radiotherapy for patients who had 
axillary sampling as compared with a complete axillary 
dissection, even in node-negative patients. However, 
it should be noted that the sentinel lymph-node 
procedure was not yet used in these trials, so care should 
be taken not to extrapolate the results to this now 
common procedure. Notwithstanding this limitation, 
the ﬁ ndings warn against the current trend of omission 
of further regional treatment after a positive sentinel 
lymph node on the basis of data for regional recurrences 
and short-term follow-up.7
As reported before, radiotherapy can increase the 
rate of deaths not related to breast cancer, mainly by 
inducing cardiac diseases and secondary cancers.8–10 This 
outcome lowers the beneﬁ t of radiotherapy on breast 
cancer mortality after longer follow-up, as shown in the 
appendix of the Article. However, modern radiotherapy 
techniques allow the non-intended dose to organs at 
risk to be decreased, while at the same time improving 
coverage of the target volumes.11,12 Therefore, continued 
follow-up is needed to understand fully the ultimate 
inﬂ uence of radiotherapy on breast-cancer-related 
mortality and on late toxic eﬀ ects.
The results of this EBCTCG meta-analysis clearly 
conﬁ rm that postmastectomy radiotherapy should 
be considered equally for patients with one to three 
involved axillary lymph nodes as it should be for 
patients with four or more aﬀ ected axillary lymph 
nodes. The same considerations concerning regional 
radiotherapy also seem to be valid for patients treated 
with breast-conserving therapy.1,2 Here, the addition of 
regional radiotherapy to whole breast irradiation adds 
less to the burden of treatment to the patient, on the 
condition that long-term toxic eﬀ ects can be avoided 
with modern radiotherapy techniques.
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In The Lancet, Nita Bhandari and colleagues’ study1 
about the eﬃ  cacy of the new 116E rotavirus vaccine 
in Indian infants oﬀ ers an opportunity to address the 
substantial lag in translation of scientiﬁ c progress for 
the beneﬁ t of the world’s most vulnerable population. 
Vaccination is considered to be second only to access 
to potable water in its potential cost-eﬀ ectiveness 
as a health-care strategy for improving child health. 
Most childhood deaths from vaccine-preventable 
diseases, such as Haemophilus inﬂ uenzae type b (Hib), 
Streptococcus pneumoniae, and rotavirus, happen in 
low-income countries.2 However, introduction of life-
saving vaccines, such as Hib conjugate vaccine, into 
national immunisation programmes in low-income 
countries has lagged by as much as 20 years behind 
implementation in high-income settings.3 Of the 
many factors responsible, constraints around vaccine 
aﬀ ordability and supply are key.
In the past decade, progress has been made in 
reducing the delay in the introduction of new childhood 
vaccines (eg, those against pneumococcus and 
rotavirus) into immunisation programmes between 
developed and developing countries. This progress 
is largely attributable to international donor funding 
coordinated under the auspices of the GAVI Alliance, 
which among other things provides coﬁ nancing for 
vaccine procurement at discounted prices negotiated 
with manufacturers for countries that meet an income 
threshold for eligibility (presently a gross national 
income per person of ≤US$1550). However, the 
sustainability of the GAVI process, in which countries 
are expected to take over ownership of funding for 
vaccine procurement once their gross national income 
per person exceeds GAVI’s eligibility threshold, remains a 
concern. One way to address this challenge is to explore 
approaches to development of low-cost, safe, and 
eﬀ ective vaccines that are aﬀ ordable for low-income 
countries.
Within this framework, the development of 116E 
rotavirus vaccine provides a model of a successful 
tripartite alliance between donors, governmental 
institutions, and a willing private sector, to ensure that 
vaccines are developed at aﬀ ordable prices. Clinical 
development of the 116E vaccine was undertaken by 
an emerging Indian vaccine manufacturer—Bharat 
Biotech—with full partnership and partial ﬁ nancial 
support from the Department of Biotechnology of the 
Indian Government, and with technical and ﬁ nancial 
support from a consortium of international partners 
and donors. In lieu of public sector support to oﬀ set 
some of the research and development costs, the 
manufacturer has committed to making the vaccine 
available to the public sector at less than $1 per dose for 
a three-dose series. This regime is in comparison to the 
discounted cost, $2·50 per dose for a two-dose series 
and $3·50 per dose for a three-dose series, of two other 
licensed rotavirus vaccines that GAVI pays for countries 
that procure vaccine through UNICEF.4 Beneﬁ ciary low-
income countries contribute $0·40 in co-ﬁ nancing for a 
full series of either vaccine.5
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